FSAGX | RYPMX | FSAGX / RYPMX | |
Total Expense Ratio | 0.68 | 1.30 | 52% |
Annual Report Gross Expense Ratio | 0.68 | 1.33 | 51% |
Fund Existence | 39 years | 32 years | - |
Gain YTD | 58.584 | 48.483 | 121% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 2500 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 2.24B | 114M | 1,968% |
Annual Yield % from dividends | 2.29 | 0.00 | - |
Returns for 1 year | 60.04 | 39.29 | 153% |
Returns for 3 years | 59.17 | 44.14 | 134% |
Returns for 5 years | 57.17 | 50.81 | 113% |
Returns for 10 years | 160.21 | 138.65 | 116% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
TAN | 33.09 | 1.27 | +3.99% |
Invesco Solar ETF | |||
BBC | 19.65 | 0.64 | +3.37% |
Virtus LifeSci Biotech Clinical Trls ETF | |||
XYLD | 38.56 | 0.13 | +0.34% |
Global X S&P 500® Covered Call ETF | |||
OPP | 8.48 | N/A | -0.01% |
RiverNorth/DoubleLine Strategic Opportunity Fund | |||
FXA | 63.99 | -0.33 | -0.51% |
Invesco CcyShrs® Australian Dllr Trust |